ROIV
Roivant Sciences Ltd.
ROIV
Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD Transcript
Nvidia (NVDA) CEO asserts AI has reached general intelligence, highlighting rapid model evolution and the income-generating potential of NVDA compute infrastructure. Intel (INTC) receives an upgrade t
Roivant Sciences NASDAQ: ROIV said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered commer
Roivant Sciences is transitioning from an asset-monetization platform to a commercial-stage biopharma, supported by a strong cash position and imminent product launches. ROIV's $4.7 billion pro forma